Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VH4367310 in Healthy Adult Participants
NCT07818915Phase 1Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing VH4367310 Group with Placebo Group (2 arms). Primary endpoints: Area under the concentration time curve from time zero to last quantifiable time point of VH4367310 and CAB at 72 weeks, Maximum observed plasma concentration of VH4367310 and CAB at 72 weeks and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
cabotegravir stearate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07818915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818915.